您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > KN-92 phosphate
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
KN-92 phosphate
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
KN-92 phosphate图片
CAS NO:1135280-28-2
规格:≥98%
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)554.98
FormulaC24H28ClN2O7PS
CAS No.1135280-28-2
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 25mg/mL
Water: N/A
Ethanol: N/A
Other info

Chemical Name: (E)-N-(2-(((3-(4-chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-4-methoxybenzenesulfonamide phosphate

InChi Key: XRQHWVVDNMJDEQ-IPZCTEOASA-N

InChi Code: InChI=1S/C24H25ClN2O3S.H3O4P/c1-27(17-5-6-19-9-11-21(25)12-10-19)18-20-7-3-4-8-24(20)26-31(28,29)23-15-13-22(30-2)14-16-23;1-5(2,3)4/h3-16,26H,17-18H2,1-2H3;(H3,1,2,3,4)/b6-5+;

SMILES Code: CN(C/C=C/C1=CC=C(Cl)C=C1)CC2=CC=CC=C2NS(=O)(C3=CC=C(OC)C=C3)=O.O=P(O)(O)O

Synonyms

KN-92 phosphate; KN-92; KN 92; KN92.

实验参考方法
In Vitro

In vitro activity: KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM). KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cell.

Cell Assay: KN-92 is an inactive derivative of KN-93. It is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM). KN-93 inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM). KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cell.

In Vivo
Animal model
Formulation & Dosage
References

World J Gastroenterol. 2007 Mar 7;13(9):1445-8; Cancer Biol Ther. 2010 Feb;9(3):224-35.